ROIVANT SCIENCES LTD. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
ROIVANT SCIENCES LTD. (ROIV) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2026-05-20
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-09-30 was $0.00.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-12-31 was $0.45.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2025 was $0.51.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2024 was -$0.40.
- ROIVANT SCIENCES LTD. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2023 was -$0.32.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | $0.00 10-Q · filed 2026-02-06 | $0.00 10-Q · filed 2026-02-06 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | $0.51 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | $0.45 10-Q · filed 2026-02-06 | $0.51 10-Q · filed 2026-02-06 | |||
| 2024-09-30 | -$0.06 10-Q · filed 2025-11-10 | $0.06 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $0.12 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | -$0.40 10-K · filed 2026-05-20 | $0.00 10-K · filed 2024-05-30 | |||
| 2023-12-31 | -$0.07 10-Q · filed 2025-02-10 | -$0.29 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | -$0.11 10-Q · filed 2024-11-12 | -$0.22 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | -$0.32 10-K · filed 2025-05-29 | $0.16 10-K · filed 2023-06-28 | |||
| 2022-03-31 | $0.00 10-K · filed 2023-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |